Macular Hole Progression following Ocriplasmin Intravitreal Injection.
Case Rep Ophthalmol Med
; 2014: 403461, 2014.
Article
en En
| MEDLINE
| ID: mdl-25580329
ABSTRACT
Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she subsequently underwent a left intravitreal ocriplasmin injection. One week after the injection, VMA had been released but with enlargement of the macular hole and a drop in her BCVA to 6/60. This persisted at 1 month after the injection. It is important to warn patients that ocriplasmin may lead to an enlargement of their macular hole with resultant loss in visual acuity.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Case Rep Ophthalmol Med
Año:
2014
Tipo del documento:
Article
País de afiliación:
Reino Unido